3 búsqueda de la palabra clave 'Cyclophosphamide'

Haploidentical stem cell transplant with post-transplant cyclophosphamide in pediatric hemophagocytic lymphohistiocytosis / Luz Natalia Builes Restrepo ; Andrés Felipe Escobar González  

Público ISBD Título : Haploidentical stem cell transplant with post-transplant cyclophosphamide in pediatric hemophagocytic lymphohistiocytosis Tipo de documento : documento electrónico Autores : Luz Natalia Builes Restrepo, ; Andrés Felipe Escobar González, Fecha de publicación : 2021 Títulos uniformes : Journal of Clinical Immunology Idioma : Inglés (eng) Palabras clave : Hemophagocytic lymphohistiocytosis  hematopoietic stem cell  transplantation  child  cyclophosphamide  haploidentical Resumen : Purpose: Primary hemophagocytic lymphohistiocytosis is a severe and uncommon disease affecting pediatric patients. Genetic abnormalities have been related to altered apoptosis and exaggerated inflammatory reactions. Chemoimmunotherapy and stem cell transplantation are treatment options, but transplant is the only curative treatment. Here we aim to describe the treatment with hematopoietic stem cell transplantation with a novel strategy and the outcomes. Methods: An observational, descriptive, case series study was performed in pediatric patients of two high complexity medical centers in Colombia. Data was collected retrospectively between 2015 and 2020. Results: We describe five pediatric cases with a diagnosis of primary hemophagocytic lymphohistiocytosis. All were treated with replete-cell haploidentical hematopoietic stem transplantation, reduced-intensity conditioning, and post-transplant cyclophosphamide, in two high-complexity centers in Colombia. All patients are alive, and one is receiving management for chronic graft-versus-host disease. Conclusion: To the best of our knowledge, there are few reports in the literature with this strategy, promising a possible alternative when there are no other donor options. Mención de responsabilidad : Diego Medina-Valencia, Daniela Cleves, Estefania Beltran, Natalia Builes, Alexis A. Franco, Andrés Felipe Escobar-González & Manuela Olaya Referencia : J Clin Immunol. 2021 Aug;41(6):1172-1177. DOI (Digital Object Identifier) : 10.1007/s10875-021-01009-3 PMID : 33687579 En línea : https://link.springer.com/article/10.1007%2Fs10875-021-01009-3 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5762 Haploidentical stem cell transplant with post-transplant cyclophosphamide in pediatric hemophagocytic lymphohistiocytosis [documento electrónico] / Luz Natalia Builes Restrepo, ; Andrés Felipe Escobar González,  . - 2021. Obra : Journal of Clinical Immunology Idioma : Inglés (eng) Palabras clave : Hemophagocytic lymphohistiocytosis  hematopoietic stem cell  transplantation  child  cyclophosphamide  haploidentical Resumen : Purpose: Primary hemophagocytic lymphohistiocytosis is a severe and uncommon disease affecting pediatric patients. Genetic abnormalities have been related to altered apoptosis and exaggerated inflammatory reactions. Chemoimmunotherapy and stem cell transplantation are treatment options, but transplant is the only curative treatment. Here we aim to describe the treatment with hematopoietic stem cell transplantation with a novel strategy and the outcomes. Methods: An observational, descriptive, case series study was performed in pediatric patients of two high complexity medical centers in Colombia. Data was collected retrospectively between 2015 and 2020. Results: We describe five pediatric cases with a diagnosis of primary hemophagocytic lymphohistiocytosis. All were treated with replete-cell haploidentical hematopoietic stem transplantation, reduced-intensity conditioning, and post-transplant cyclophosphamide, in two high-complexity centers in Colombia. All patients are alive, and one is receiving management for chronic graft-versus-host disease. Conclusion: To the best of our knowledge, there are few reports in the literature with this strategy, promising a possible alternative when there are no other donor options. Mención de responsabilidad : Diego Medina-Valencia, Daniela Cleves, Estefania Beltran, Natalia Builes, Alexis A. Franco, Andrés Felipe Escobar-González & Manuela Olaya Referencia : J Clin Immunol. 2021 Aug;41(6):1172-1177. DOI (Digital Object Identifier) : 10.1007/s10875-021-01009-3 PMID : 33687579 En línea : https://link.springer.com/article/10.1007%2Fs10875-021-01009-3 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5762

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD001687	AC-2021-013	Archivo digital	Producción Científica	Artículos científicos	Disponible

Hemorrhagic cystitis after haploidentical transplantation with post-transplantation cyclophosphamide: protective effect of MESNA continuous infusion / Marcos Arango Barrientos  

Público ISBD Título : Hemorrhagic cystitis after haploidentical transplantation with post-transplantation cyclophosphamide: protective effect of MESNA continuous infusion Tipo de documento : documento electrónico Autores : Marcos Arango Barrientos, Fecha de publicación : 2020 Títulos uniformes : Biology of Blood and Marrow Transplantation Idioma : Inglés (eng) Palabras clave : BK virus  Cyclophosphamide  Cystitis  Haploidentical  MESNA  Transplantation Resumen : Hemorrhagic cystitis (HC) is an important complication after haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with post-transplantation cyclophosphamide (PT-CY). Sodium 2-mercaptoethanesulfonate (MESNA) can prevent bladder injury when given with PT-CY. However, the best way to deliver MESNA is not known. This study assessed the incidence of HC after haplo-HSCT with PT-CY with 2 different methods of MESNA administration. The cumulative incidence of HC was lower in patients who received MESNA as a continuous infusion compared with those who received it as an intermittent bolus (5.6% versus 27.8%; P = .01). MESNA administration as an infusion was associated with a lower risk of developing HC (hazard ratio [HR], .19; 95% confidence interval [CI], .04 to .86; P = .02) on univariate analysis. This effect remained significant after adjustment in multivariate analysis (HR, .21; 95% CI, .04 to .88; P = .03). MESNA delivered as a continuous infusion is a simple and potentially useful way to prevent HC after PT-CY. Mención de responsabilidad : Marcos Arango, Doris Cardona Referencia : Biol Blood Marrow Transplant. 2020 Aug;26(8):1492-1496 DOI (Digital Object Identifier) : 10.1016/j.bbmt.2020.04.028 PMID : 32417488 En línea : https://linkinghub.elsevier.com/retrieve/pii/S1083879120302834 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5119 Hemorrhagic cystitis after haploidentical transplantation with post-transplantation cyclophosphamide: protective effect of MESNA continuous infusion [documento electrónico] / Marcos Arango Barrientos,  . - 2020. Obra : Biology of Blood and Marrow Transplantation Idioma : Inglés (eng) Palabras clave : BK virus  Cyclophosphamide  Cystitis  Haploidentical  MESNA  Transplantation Resumen : Hemorrhagic cystitis (HC) is an important complication after haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with post-transplantation cyclophosphamide (PT-CY). Sodium 2-mercaptoethanesulfonate (MESNA) can prevent bladder injury when given with PT-CY. However, the best way to deliver MESNA is not known. This study assessed the incidence of HC after haplo-HSCT with PT-CY with 2 different methods of MESNA administration. The cumulative incidence of HC was lower in patients who received MESNA as a continuous infusion compared with those who received it as an intermittent bolus (5.6% versus 27.8%; P = .01). MESNA administration as an infusion was associated with a lower risk of developing HC (hazard ratio [HR], .19; 95% confidence interval [CI], .04 to .86; P = .02) on univariate analysis. This effect remained significant after adjustment in multivariate analysis (HR, .21; 95% CI, .04 to .88; P = .03). MESNA delivered as a continuous infusion is a simple and potentially useful way to prevent HC after PT-CY. Mención de responsabilidad : Marcos Arango, Doris Cardona Referencia : Biol Blood Marrow Transplant. 2020 Aug;26(8):1492-1496 DOI (Digital Object Identifier) : 10.1016/j.bbmt.2020.04.028 PMID : 32417488 En línea : https://linkinghub.elsevier.com/retrieve/pii/S1083879120302834 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5119

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD001376	AC-2020-054	Archivo digital	Producción Científica	Artículos científicos	Disponible

Fever after peripheral blood stem cell infusion in haploidentical transplantation with post-transplant cyclophosphamide / Marcos Arango Barrientos ; Juan Felipe Combariza Vallejo  

Público ISBD Título : Fever after peripheral blood stem cell infusion in haploidentical transplantation with post-transplant cyclophosphamide Tipo de documento : documento electrónico Autores : Marcos Arango Barrientos, ; Juan Felipe Combariza Vallejo, Fecha de publicación : 2017 Títulos uniformes : Hematology/Oncology and Stem Cell Therapy Idioma : Inglés (eng) Palabras clave : Cyclophosphamide  fever  haploidentical hematopoietic stem cell transplantation  peripheral blood stem cell transplantation  prognosis Resumen : Objective/background: Noninfection-related fever can occur after peripheral blood stem cell infusion in haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide. The objective of this study was to analyze the incidence of fever and characterize some clinical features of affected patients. Methods: A retrospective case-series study with 40 patients who received haploidentical hematopoietic stem cell transplantation was carried out. Results Thirty-three patients (82.5%) developed fever; no baseline characteristic was associated with its development. Median time to fever onset was 25.5 h (range, 9.5–100 h) and median peak temperature was 39.0 °C (range, 38.1–40.5 °C). Not a single patient developed hemodynamic or respiratory compromise that required admission to the intensive care unit. Fever was not explained by infection in any case. Ninety-one percent of the febrile episodes resolved within 96 h of cyclophosphamide administration. No significant difference in overall survival, event-free survival, or graft versus host disease-free/relapse-free survival was found in the group of febrile individuals after peripheral blood stem cell infusion. Conclusion: Fever after peripheral blood stem cell infusion in this clinical setting was common; it usually subsides with cyclophosphamide administration. The development of fever was not associated with an adverse prognosis. Mención de responsabilidad : Marcos Arango, Juan F Combariza Referencia : Hematol Oncol Stem Cell Ther. 2017 Jun;10(2):79-84. DOI (Digital Object Identifier) : 10.1016/j.hemonc.2017.03.001 PMID : 28390959 En línea : https://linkinghub.elsevier.com/retrieve/pii/S1658-3876(17)30031-6 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4047 Fever after peripheral blood stem cell infusion in haploidentical transplantation with post-transplant cyclophosphamide [documento electrónico] / Marcos Arango Barrientos, ; Juan Felipe Combariza Vallejo,  . - 2017. Obra : Hematology/Oncology and Stem Cell Therapy Idioma : Inglés (eng) Palabras clave : Cyclophosphamide  fever  haploidentical hematopoietic stem cell transplantation  peripheral blood stem cell transplantation  prognosis Resumen : Objective/background: Noninfection-related fever can occur after peripheral blood stem cell infusion in haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide. The objective of this study was to analyze the incidence of fever and characterize some clinical features of affected patients. Methods: A retrospective case-series study with 40 patients who received haploidentical hematopoietic stem cell transplantation was carried out. Results Thirty-three patients (82.5%) developed fever; no baseline characteristic was associated with its development. Median time to fever onset was 25.5 h (range, 9.5–100 h) and median peak temperature was 39.0 °C (range, 38.1–40.5 °C). Not a single patient developed hemodynamic or respiratory compromise that required admission to the intensive care unit. Fever was not explained by infection in any case. Ninety-one percent of the febrile episodes resolved within 96 h of cyclophosphamide administration. No significant difference in overall survival, event-free survival, or graft versus host disease-free/relapse-free survival was found in the group of febrile individuals after peripheral blood stem cell infusion. Conclusion: Fever after peripheral blood stem cell infusion in this clinical setting was common; it usually subsides with cyclophosphamide administration. The development of fever was not associated with an adverse prognosis. Mención de responsabilidad : Marcos Arango, Juan F Combariza Referencia : Hematol Oncol Stem Cell Ther. 2017 Jun;10(2):79-84. DOI (Digital Object Identifier) : 10.1016/j.hemonc.2017.03.001 PMID : 28390959 En línea : https://linkinghub.elsevier.com/retrieve/pii/S1658-3876(17)30031-6 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4047

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD000645	AC-2017-034	Archivo digital	Producción Científica	Artículos científicos	Disponible